Targeted therapy-induced diarrhea: A review of the literature

Critical Reviews in Oncology/Hematology

Volumn 90, Issue 2, 2014, Pages 165-179

  Pessi, M A ^a   Zilembo, N ^b   Haspinger, E R ^b   Molino, L ^b   Di Cosimo, S ^b   Garassino, M ^b   Ripamonti, C I ^a  

^a Supportive Care in Cancer Unit Department of Hematology and Pediatric Onco Hematology   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Assessment; Diarrhea; Incidence; Targeted therapy; Treatment

Indexed keywords

AFATINIB; AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IPILIMUMAB; LAPATINIB; LOPERAMIDE; OCTREOTIDE; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PLACEBO; REGORAFENIB; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; CAPECITABINE; DOCETAXEL; PEMETREXED; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANEMIA; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY METASTASIS; LUNG NON SMALL CELL CANCER; MELANOMA; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; STOMATITIS; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; ABDOMINAL PAIN; ADENOCARCINOMA; ANTIDIARRHEAL ACTIVITY; CANCER SURVIVAL; CLINICAL PRACTICE; DEHYDRATION; DIET THERAPY; DIGESTIVE SYSTEM PERFORATION; FEVER; FLUID THERAPY; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HYPERTENSION; ILEUS; INOPERABLE CANCER; INTESTINE PERFORATION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; METASTASIS; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NAIL DISEASE; NEOPLASM; NON SMALL CELL LUNG CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PERITONEAL DISEASE; PHARMACOGENETICS; PROTEIN TARGETING; RECTUM HEMORRHAGE; SKIN DISEASE; SOFT TISSUE SARCOMA; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SYSTEMIC MASTOCYTOSIS; VOMITING; CHEMICALLY INDUCED;

ANTINEOPLASTIC AGENTS; DIARRHEA; HUMANS;

EID: 84897574426     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.11.008     Document Type: Review

References (108)

1. Cleeland C.S., Mendoza T.R., Wang X.S., Chou C., Harle M.T., Morrissey M., et al. Assessing symptom distress in cancer patients: the M.D. Anderson symptom inventory. Cancer 2000, 89:1634-1646.
2. Saltz L.B. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 2003, 1:35-46.
3. Benson A.B., Ajani J., Catalano R., Engelking C., Kornblau S.M., Martenson J.A., et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004, 22:2918-2926.
4. Solomon R., Cherny N. Constipation and diarrhea in patients with cancer. Cancer J 2006, 12:355-364.
5. Hawley P.H., Baldwin C. Long-term real-life usefulness of the Victoria bowel performance scale. J Pain Symptom Manage 2012, 44:e2-e3.
6. Mercadante S. Diarrhea, malabsorption and constipation. Principles and Practice of Palliative Care and Supportive Oncology 2013, 175-192. Lippincott Williams & Wilkins, a Wolters Kluwer business, Philadelphia, PA. 4th ed. A.M. Berger, J.L. Shuster, J.H. Von Roenn (Eds.).
7. Sykes N. Constipation and diarrhoea. Oxford Textbook of Palliative Medicine 2004, 483. Oxford University Press, New York, NY. 3rd ed. D. Doyle, G. Hanks, N.I. Cherny, M. Fallon, S. Kaasa, R.K. Portenoy (Eds.).
8. Goldfinger S.E. Constipation and diarrhea. Harrison's Principles of Internal Medicine 1991, 256-259. McGraw-Hill, Toronto. I.D. Wilson, E. Braunwald, K.J. Isselbacher (Eds.).
9. Harandi A., Zaidi A.S., Stocker A.M., Laber D.A. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009, 567:486.
10. Hirsh V. Management treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol 2011, 18:126-138.
11. Frieling T., Heise J., Wassilew S.W. Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. Dtsch med Wochenschr 2009, 134:1464-1466.
12. Andrews S., Holden R. Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastastic melanoma. Cancer Manage Res 2012, 4:299-307.
13. Weber J.S., Kähler K.C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012, 30:2691-2697.
14. http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
15. Cherny N.I. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage 2008, 36:413-423.
16. Danielsen A.J., Maihle N.J. The EGF/ErbB receptor family and apoptosis. Growth Factors 2002, 20:1-15.
17. Bianco R., Gelardi T., Damiano V., Ciardiello F., Tortora G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 2007, 39:1416-1431.
18. Stein A., Voigt W., Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010, 2:51-63.
19. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
20. Davila M., Bresalier R.S. Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol 2008, 5:682-696.
21. Vincenzi B., Schiavon G., Pantano F., Santini D., Tonini G. Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nat Clin Pract Oncol 2008, 5:455-465.
22. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21:2237-2246.
23. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
24. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
25. Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y., Kim H.T., et al. First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
26. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG 3405): an open label randomised phase 3 trial. Lancet Oncol 2009, 11:121-128.
27. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
28. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: results from a randomised, placebo-controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
29. Lee D.H., Park K., Kim J.H., Lee J.S., Shin S.W., Kang J.H., et al. Randomized phase III trial of gefitinib versus docetaxel in non small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010, 16:1307-1314.
30. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
31. Lemos C., Giovannetti E., Zucali P.A., Assaraf Y.G., Scheffer G.L., van der Straaten T., et al. Impact of ABCG2 polymorphism on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 2011, 12:159-170.
32. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
33. Ciuleanu T., Stelmakh L., Cicenas S., Miliauskas S., Grigorescu A.C., Hillenbach C., et al. Efficacy and safety of erlotinib versus chemotherapy in non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012, 13:300-308.
34. Gridelli C., Ciardiello F., Gallo C., Feld R., Butts C., Gebbia V., et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell-lung cancer: the TORCH randomized trial. J Clin Oncol 2012, 30:3002-3011.
35. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib vs standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicenter, open-label, randomised phase III trial. Lancet Oncol 2012, 13:239-246.
36. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non small cell lung cancer: a multicenter, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
37. Reck M., von Zandwijk N., Gridelli C., Baliko Z., Rischin D., Allan S., et al. Erlotinib in advanced non-small cell lung cancer (NSCLC): efficacy and safety findings of the global phase IV TRUST study. J Thorac Oncol 2010, 5:1616-1622.
38. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., et al. Afatinib versus placebo for patients with advanced, metastatic non small cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13:528-538.
39. Yang J.C.H., Shih J.Y., Su W.C., Hsia T.C., Tsai C.M., Ou S.H., et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13:539-548.
40. Sequist L.V., Yang J.C.H., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
41. Cameron D., Casey M., Press M., Lindquist D., Pienkowski T., Romieu C.G., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:533-543.
42. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
43. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
44. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., et al. NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
45. Untch M., Loibl S., Bischoff J., Eidtmann H., Kaufmann M., Blohmer J.U., et al. German Breast Group (GBG), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012, 13:135-144.
46. Burris H.A., 3rd, Hurwitz H.I., Dees E.C., Dowlati A., Blackwell K.L., O'Neil B., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, 23:5305-5313.
47. Moy B., Goss P.E. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007, 12:756-765.
48. Au H.J., Eiermann W., Robert N.J., Pienkowski T., Crown J., Martin M., et al. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 study. Oncologists 2013, 18:812-818.
49. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positiv breast cancer. N Engl J Med 2005, 353:1659-1672.
50. Sawaki M., Ito Y., Tada K., Mizunuma N., Takahashi S., Horikoshi N., et al. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER2/Neu overexpressing metastatic breast cancer. Tumori 2004, 90:40-43.
51. Huober J., Fasching P.A., Barsoum M., Petruzelka L., Wallwiener D., Thomssen C., et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012, 21:27-33.
52. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
53. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P., Miles D., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28:1138-1144.
54. Baselga J., Cortés J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al. CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
55. Cortés J., Fumoleau P., Bianchi G.V., Petrella T.M., Gelmon K., Pivot X., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012, 30:1594-1600.
56. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009, 373:1525-1531.
57. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
58. Van Cutsem E., Siena S., Humblet Y., Canon J.L., Maurel J., Bajetta E., et al. An open-label, single arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008, 19:92-98.
59. Jean G.W., Shah S.R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008, 28:742-754.
60. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
61. Bossi P., Kornek G., Lanzetta G., Rozzi A., Füreder T., Locati L., et al. Safety and feasibility of every-other week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. Head Neck 2013, 35:1471-1474.
62. Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2311-2319.
63. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2008, 27:663-671.
64. Reynold N., Wagstaff A.J. Cetuximab in the treatment of metastatic colorectal cancer. Drugs 2004, 64:109-118.
65. Peeters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:4706-4713.
66. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., et al. A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2008, 27:672-680.
67. Schlemmer M., Bauer S., Schütte R., Hartmann J.T., Bokemeyer C., Hosius C., et al. Activity and side effects of Imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial. Eur J Med Res 2011, 16:206-212.
68. Dematteo R.P., Ballman K.V., Antonescu C.R., Maki R.G., Pisters P.W., Demetri G.D., et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
69. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
70. Grothey A., Van Cutsem E., Sobrero A., Siena S., Falcone A., Ychou M., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312.
71. Aprile G., Macerelli M., Giuliani F. Regorafenib for gastrointestinal malignancies from preclinical data to clinical results of a novel multi-target inhibitor. BioDrugs 2013, 27:213-224.
72. Smith D.C., Smith M.R., Sweeney C., Elfiky A.A., Logothetis C., Corn P.G., et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013, 31:412-419.
73. Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep 2013, 15:76-82.
74. Deininger M., O'Brien S.G., Ford J.M., Druker B.J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003, 21:1637-1647.
75. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
76. Gore M.E., Szczylik C., Porta C., Bracarda S., Bjarnason G.A., Oudard S., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757-763.
77. Aparicio-Gallego G., Blanco M., Figueroa A., García-Campelo R., Valladares-Ayerbes M., Grande-Pulido E., et al. New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther 2011, 10:2215-2223.
78. Roodhart J.M., Langenberg M.H., Witteveen E., Voest E.E. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008, 3:132-143.
79. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
80. Beck J., Procopio G., Bajetta E., Keilholz U., Negrier S., Szczylik C., et al. Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011, 22:1812-1823.
81. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausová J., Macarulla T., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase iii randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012, 30:3499-3506.
82. Rini B.I., Escudier B., Tomczak P., Kaprin A., Szczylik C., Hutson T.E., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
83. Presta L.G., Chen H., O'Connor S., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
84. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
85. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
86. Robert N.J., Diéras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
87. Miles D.W., Chan A., Dirix L.Y., Cortés J., Pivot X., Tomczak P., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
88. Pivot X., Schneeweiss A., Verma S., Thomssen C., Passos-Coelho J.L., Benedetti G., et al. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer 2011, 47:2387-2395.
89. Leboulleux S., Bastholt L., Krause T., de la Fouchardiere C., Tennvall J., Awada A., et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012, 13:897-905.
90. Campbell M., Seib C., Gosnell J. Vandetanib and the management of advanced medullary thyroid cancer. Curr Opin Oncol 2013, 25:39-43.
91. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Global ARCC trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007, 356:2271-2281.
92. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
93. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
94. Menzies A.M., Long G.V., Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des, Devel Ther 2012, 6:391-405.
95. Chapman P., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
96. Long G., Trefzer U., Davies M., Kefford R.F., Ascierto P.A., Chapman P.B., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 23:1087-1095.
97. Falchook G.S., Lewis K.D., Infante J.R., Gordon M.S., Vogelzang N.J., DeMarini D.J., et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:782-789.
98. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114.
99. Kirkwood J.M., Bastholt L., Robert C., Sosman J., Larkin J., Hersey P., et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012, 18:555-567.
100. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced alk-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
101. Ibrahim R., Berman D.M., DePril V., Humphrey R.W., Chen T., Messina M., et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011, 29. Suppl: Abstract 8583.
102. Hodi F., O'Day S., McDermott D., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
103. Andrews S., Holden R. Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res 2012, 4:299-307.
104. Zidan J., Haim N., Beny A., Stein M., Gez E., Kuten A. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 2001, 12:227-229.
105. Karthaus M., Ballo H., Abenhardt W., Steinmetz T., Geer T., Schimke J., et al. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (Cpt-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 2005, 68:326-332.
106. Lenfers B.H., Loeffler T.M., Droege C.M., Hausamen T.U. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999, 10:1251-1253.
107. Wolchok J.D., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma. A randomized, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164.
108. Andrew S., Holden R. Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manage Res 2012, 4:299-307.